Published: February 28, 2013

Introduction {#sec1}
============

The Raf/MEK/ERK pathway is among the most thoroughly studied downstream effectors of activated Ras ([@bib58]). Deregulation of the pathway is implicated in both developmental disorders and cancer ([@bib31]; [@bib44]). Consequently, numerous RAF and MEK inhibitors aimed at blocking ERK activation have been designed ([@bib9]; [@bib37]).

The dual specificity kinases MEK1 and MEK2 are activated by RAF and mediate phosphorylation of ERK1 and ERK2 ([@bib39]). MEK1 and MEK2 are very similar but differ structurally in a proline-rich domain in the C-terminal half of the catalytic core, which in MEK1 contains the negative regulatory phosphorylation sites T286, targeted by Cdk5 mainly in postmitotic neurons, and T292, essential for the negative feedback regulation of MEK by ERK1 and ERK2 ([@bib39]).

MEK1 and MEK2 also bind differentially to scaffolds such as MP1, which plays a role in ERK1 activation at late endosomes ([@bib53]), and IQGAP1, which regulates adhesion/migration, promotes signaling from MEK1 to ERK, and attenuates MEK2/ERK signaling ([@bib40]).

Finally, disruption of the *mek1* gene in vivo causes abnormal placenta development and lethality around embryonic day 9.5 ([@bib3]; [@bib8]; [@bib16]), while *mek2*^−/−^ mice are normal ([@bib1]).

We have recently reported that MEK1 is essential for the regulation of the timing and strength of ERK signaling. By phosphorylating the T292 site in the proline-rich region of MEK1, ERK exerts negative feedback control on MEK1/MEK2 dimers. If MEK1 is absent, this control is disabled, leading to increased ERK signaling ([@bib8]).

Besides this negative feedback within the pathway, ERK can interfere with phosphatidylinositol-3 kinase (PI3K)/AKT signaling, another major protumorigenic Ras effector ([@bib28]; [@bib45]). In response to growth factors, PI3K converts phosphatidylinositol 4,5 diphosphate (PIP~2~) in the second messenger phosphatidylinositol 3,4,5 triphosphate (PIP~3~). AKT binds to PIP~3~ via its pleckstrin homology (PH) domain and translocates to the membrane, where it is activated by phosphorylation of T308 and S473. Tumor suppressor phosphatase and tensin homolog deleted on chromosome ten (PTEN) dephosphorylates PIP~3~, counteracting PI3K activity and restraining AKT activation ([@bib28]; [@bib45]). Inhibition or silencing of MEK increases growth factor-stimulated AKT activation ([@bib19]; [@bib54]; [@bib62]), a finding which was linked to ERK-mediated inhibition of PI3K recruitment to the epidermal growth factor (EGF) receptor via phosphorylation of the adaptor GAB1 ([@bib26]; [@bib64]).

We show that MEK1 is required for the control of PIP~3~ accumulation at the cell membrane, which it regulates by ensuring the proper localization of PTEN in the context of a ternary complex with a multiprotein adaptor, MAGI1. MEK1 ablation deregulates the AKT pathway which, in vivo, induces a breach of peripheral self tolerance and myeloproliferation.

Results {#sec2}
=======

MEK1 Is Essential for the Negative Regulation of AKT Signaling {#sec2.1}
--------------------------------------------------------------

We monitored the impact of MEK1 on AKT signaling in wild-type (WT) and MEK1 knockout (KO) mouse embryonic fibroblasts (MEFs) ([@bib8]) stimulated with epidermal growth factor (EGF). Phosphorylation of AKT and its downstream effectors mTOR, GSK3β, and S6K was reproducibly enhanced in MEK1-deficient cells ([Figures 1](#fig1){ref-type="fig"}A and 1C). The increase in AKT phosphorylation was rescued by the re-expression of full-length MEK1 ([Figure 1](#fig1){ref-type="fig"}B). The levels of the membrane lipid PIP~3~, necessary for AKT activation ([@bib28]), were significantly higher in KO MEFs than in control cells ([Figure 1](#fig1){ref-type="fig"}D and [Figures S1](#app2){ref-type="sec"}A and S1B available online). In contrast, PI3K expression and activity ([Figures 1](#fig1){ref-type="fig"}E and [S1](#app2){ref-type="sec"}C) were comparable in WT and KO cells, as were PTEN expression and the EGF-induced dephosphorylation of the C-terminal residues which negatively regulate PTEN activity, its association with PDZ-containing proteins ([@bib38]; [@bib55]) and with PIP~2~ ([Figure S1](#app2){ref-type="sec"}D). However, PTEN was hardly detectable at the membrane of KO MEFs, even after EGF stimulation ([Figures 1](#fig1){ref-type="fig"}F, [S1](#app2){ref-type="sec"}E, and S1F), and membrane-associated PTEN activity was greatly reduced ([Figure 1](#fig1){ref-type="fig"}G). Consistently, focal adhesion kinase (FAK), a membrane-associated PTEN protein substrate ([@bib51]; [@bib60]), was also hyperphosphorylated in KO cells ([Figure S1](#app2){ref-type="sec"}G). MEK1 ablation did not impact the specific activity of membrane PTEN; in the cytosol, activity transiently increased at 5 min of EGF treatment ([Figure 1](#fig1){ref-type="fig"}G). PTEN can be regulated by a variety of posttranslational modifications and by the interaction with other proteins ([@bib45]); which of these mechanisms is responsible for this transient increase in cytosolic PTEN activity is currently unknown. Thus, MEK1 is required for correct membrane localization of PTEN and for limiting PIP~3~ accumulation and AKT activation.

MEK1 KO Mice Develop Myeloproliferation and Autoimmune Disease {#sec2.2}
--------------------------------------------------------------

To investigate the function of MEK1 in vivo, we used mice with epiblast-restricted MEK1 ablation (*mek1*^f/f^; *Sox2Cre* mice \[[@bib8]\], referred to as KO mice). These animals, in particular the females, had a significantly decreased survival rate ([Figure 2](#fig2){ref-type="fig"}A). Increased numbers of circulating lymphocytes could be detected in the blood of 1- to 3-month-old mice; this was exacerbated in old MEK1 KO animals, in which it was accompanied by granulocytosis and thrombocytosis ([Figure 2](#fig2){ref-type="fig"}B). By 8--10 months of age, 83% MEK1-deficient females had developed severe splenomegaly ([Figure 2](#fig2){ref-type="fig"}C), hepatomegaly with lesser frequency ([Figure 2](#fig2){ref-type="fig"}D; observed in 45% of the animals), and, occasionally, lymphadenopathy. Liver and spleen showed effacement of architecture, extramedullary hematopoiesis, accumulation of atypical megakaryocytes, and fibrosis ([Figures 2](#fig2){ref-type="fig"}E and [S2](#app2){ref-type="sec"}A). Splenomegaly correlated with a massive increase in immature Mac1^+^Gr1^+^ myeloid cells ([Figure 2](#fig2){ref-type="fig"}F), a population observed in pathological conditions such as cancer and autoimmunity ([@bib14]). KO bone marrow and splenocytes isolated from young, unaffected animals gave rise to a significant higher number of colony forming units in semisolid media, indicating a cell-autonomous phenotype ([Figure S2](#app2){ref-type="sec"}B). In addition, KO spleens contained significantly increased numbers of T (CD3^+^) and B (CD19^+^) cells ([Figure 2](#fig2){ref-type="fig"}F). The CD4^+^/CD8^+^ ratio was normal, but more T and B cells were activated, as shown by the coexpression of the activation marker CD69 with CD3 and CD19 ([Figure 2](#fig2){ref-type="fig"}G). Despite the autoimmune disease, splenic Tregs were not decreased (data not shown). A slight increase in activated T cells was the only phenotype detected in the spleen of young KO mice ([Figure S2](#app2){ref-type="sec"}C). In contrast to the marked phenotypic alterations in spleen and liver, KO thymi were normal in terms of cellularity and subset distribution ([Figure S2](#app2){ref-type="sec"}D).

Among the nonhematopoietic organs, KO lungs showed thickening of the interstitial alveolar spaces with vascular congestion ([Figure S2](#app2){ref-type="sec"}E); however, the kidneys were the organs most severely affected. The tubules were dilated and filled with proteinaceous material, and the glomeruli displayed signs of focal proliferation and sclerosis reminiscent of glomerulonephritis, accompanied by the deposition of immunocomplexes in the glomeruli ([Figures 3](#fig3){ref-type="fig"}A and 3B). In addition, antibodies against double-stranded DNA (dsDNA), a hallmark of lupus-like autoimmune diseases, were detected in the sera of seven out of seven KO 5- to 10-month-old females ([Figure 3](#fig3){ref-type="fig"}C; titer of 1:100 in five mice; 1:1000 in two mice). This correlated with a marked increase in the concentrations of serum immunoglobulins (IgG1, IgG2b, IgA) and in the frequency of IgA and IgG-producing B cells affected mice ([Figures 3](#fig3){ref-type="fig"}D and 3E). Circulating BAFF and interleukin-10 (IL-10) ([Figure 3](#fig3){ref-type="fig"}F), crucially implicated in the pathogenesis of lupus-like disease ([@bib48]), were also elevated, and the frequency of cells producing IL-10, GM-CSF, transforming growth factor β, and interferon γ (IFNγ) was elevated to varying degrees ([Figure S3](#app2){ref-type="sec"}A). In all cases, the increase was most pronounced in CD4+ lymphocytes. IFNα, IL-3, IL-6, IL-17, and IL-23 were tested but proved similar in WT and KO (data not shown).

Thus, the KO mice are prone to develop both myeloproliferation and a lupus-like autoimmune disorder reminiscent of those reported for *pten*^+/−^ ([@bib11]), hematopoetic ([@bib18]; [@bib61]) or T cell-restricted PTEN KO mice ([@bib29]; [@bib49]), and constitutively active AKT transgenic mice ([@bib23]; [@bib35]).

MEK1 Ablation Deregulates AKT Activation and Impairs Activation-Induced Cell Death {#sec2.3}
----------------------------------------------------------------------------------

The AKT deregulation caused by PTEN mislocalization ([Figures 1](#fig1){ref-type="fig"} and [S1](#app2){ref-type="sec"}) could contribute to the phenotypes of MEK1 KO mice. Indeed, AKT phosphorylation was detected to variable extents in KO kidneys, livers, lungs, spleens, and lymphnodes ([Figures 3](#fig3){ref-type="fig"}A, [S2](#app2){ref-type="sec"}F, and S2G). In contrast, ERK phosphorylation, deregulated in cultured fibroblasts and in some organs in vivo ([@bib8]), was not affected ([Figure S2](#app2){ref-type="sec"}H). Given the poor conditions of these animals, however, it is impossible to distinguish whether this phosphorylation is cause or consequence of the phenotypes observed. We therefore investigated in more detail the spleens of young MEK1 KO mice, which were normal but for a slight increase in the number of activated T cells ([Figure S2](#app2){ref-type="sec"}C). pAKT ([Figure 3](#fig3){ref-type="fig"}G) was increased and membrane PTEN was decreased ([Figure 3](#fig3){ref-type="fig"}H) in the KO samples. Increased pAKT was also observed in KO CD4+ T cells stimulated with anti-CD3/CD28 ([Figure 3](#fig3){ref-type="fig"}I). KO CD4+ T lymphocytes and B cells were less responsive to activation-induced cell death (AICD), a phenotype abrogated by a PI3K, but not by a MEK inhibitor ([Figures 3](#fig3){ref-type="fig"}J and 3K), and to Fas-induced apoptosis ([Figure 3](#fig3){ref-type="fig"}L). In contrast, other functions of CD4+ cells and B cells, such as their ability to proliferate and express the activation marker CD69 in response to T or B cell receptor stimulation, were unaffected ([Figures S3](#app2){ref-type="sec"}B and S3C), indicating that the resistance to AICD is the major cell-autonomous phenotype. KO MEFs were also resistant to various proapoptotic stimuli ([Figures S3](#app2){ref-type="sec"}D and S3E). This is reminiscent of the impaired apoptosis observed in PTEN-deficient lymphocytes ([@bib7]; [@bib11]; [@bib29]; [@bib50]) and fibroblasts ([@bib47]).

A MEK1/MAGI-1/PTEN Complex Regulates PTEN Membrane Recruitment {#sec2.4}
--------------------------------------------------------------

To gain insight in PTEN regulation by MEK1, we tested whether MEK1 and PTEN interacted in cells. PTEN was present in MEK1 immunoprecipitates (IPs) from growth-factor stimulated fibroblasts ([Figure 4](#fig4){ref-type="fig"}A). Conversely, MEK1 but not MEK2 could be detected in PTEN IPs from WT cells, and interaction was enhanced upon growth factor stimulation ([Figures 4](#fig4){ref-type="fig"}B and 4D). Recombinant PTEN and MEK1 did not interact in vitro ([Figure S4](#app2){ref-type="sec"}A), indicating a requirement for a scaffold protein that, since MEK1 impacts membrane localization of PTEN, should be involved in PTEN membrane recruitment. Membrane-associated guanylate kinase (MAGUK) family member with inverted domain structure-1 (MAGI1) is a PTEN binding partner which localizes to the plasma membrane, specifically in domains such as adherens junctions, which act as focal points for the regulation of PIP~3~ pools and therefore control the recruitment and activation of AKT by assembling signaling complexes involving E-cadherin, β-catenin, and PTEN ([@bib4]; [@bib24]). MAGI1 contains six PDZ domains, a guanylate kinase (GUK) domain, and two WW domains flanked by two PDZ domains ([@bib12]); PTEN binds selectively to the second PDZ domain of MAGI1 ([@bib24]). Several isoforms and splice variants of MAGI1 are expressed in different cell types ([@bib12]; [@bib13]; [@bib24]; [@bib25]; [@bib59]). MAGI1 in MEFs appeared as multiple bands, with a predominant band of approximately 100 kD (MAGI1~100~, marked by an asterisk) and two further bands of about 130 and 150 kD. The 100 kD isoform was selectively recruited to the membrane upon growth factor stimulation of WT cells, but MEK1 ablation prevented MAGI1 membrane translocation ([Figure 4](#fig4){ref-type="fig"}C). In addition, MAGI1~100~ was detected in PTEN IPs from WT but not MEK1 KO MEF whole-cell lysates and membrane fractions ([Figures 4](#fig4){ref-type="fig"}D and [S4](#app2){ref-type="sec"}B), and the interaction between PTEN and MAGI1 could be restored by addition of recombinant MEK1 to the KO lysates prior to PTEN immunoprecipitation ([Figure 4](#fig4){ref-type="fig"}E). MAGI1 was detectable in MEK1, but not in MEK2 IPs ([Figures S4](#app2){ref-type="sec"}C and S4D). Thus, MEK1 is essential for the formation of a complex containing MAGI1 and PTEN and for their membrane translocation upon growth factor stimulation. The kinetics of EGF-induced complex formation was similar to that of MEK1 phosphorylation on the ERK-dependent negative regulatory residue T292, unique to MEK1. pT292 MEK1 was enriched in PTEN immunoprecipitates, as assessed by densitometry (10% of total pT292 MEK1 versus 0.7% of total MEK1 in PTEN IPs from EGF-stimulated cells), while neither the activating RAF-dependent (S218 and S222) nor the PAK-dependent (S298) sites correlated well with binding ([Figure 4](#fig4){ref-type="fig"}D). Thus, T292 might work as a temporal switch, ensuring that ternary complex formation and membrane translocation occur after ERK activation.

MEK1 ablation decreases PTEN membrane localization and increases AKT phosphorylation in splenocytes ([Figures 3](#fig3){ref-type="fig"}G and 3H). MAGI1~100~ is expressed in spleen, and it is detectable, together with MEK1, in PTEN immunoprecipitates from WT but not KO organs ([Figure 4](#fig4){ref-type="fig"}F). Therefore, the mechanism described for the MEFs operates also in the spleen. In line with the lack of phenotype and AKT activation in KO thymi ([Figures S2](#app2){ref-type="sec"}D and S2G), MAGI1~100~ was not expressed in thymus, and MEK1 was absent in PTEN immunoprecipitates from this organ ([Figure 4](#fig4){ref-type="fig"}F).

In MEFs, MAGI1 is the most efficiently expressed MAGI protein ([Figure S4](#app2){ref-type="sec"}E). Consistently, MAGI1 knockdown efficiently abrogated PTEN binding to MEK1 ([Figure 4](#fig4){ref-type="fig"}G), reduced PTEN membrane localization, and increased AKT activation ([Figures S4](#app2){ref-type="sec"}F and S4G). Thus, MAGI1 is the scaffold mediating the interaction between MEK1 and PTEN. The ternary complex was also found in human, rat, and chicken cells ([Figure S4](#app2){ref-type="sec"}H) and in monkey cells ([Figure 5](#fig5){ref-type="fig"}H), indicating that it represents an important conserved regulatory principle.

We next examined the interaction of MEK1 with selected MAGI1 domains expressed as myc-fusion proteins ([@bib59]). The GUK and, to a greater extent, the two WW domains were detectable in MEK1 IPs, whereas the PTEN-binding PDZ domains were not ([Figure 5](#fig5){ref-type="fig"}A). Consistently, deletion of either the GUK or the WW domains reduced MAGI1 binding to MEK1, and deletion of both domains abolished it ([Figure 5](#fig5){ref-type="fig"}B). MEK1 was detectable in full-length MAGI1, GUK, and WW domain IPs. GUK domains are phosphopeptide-binding modules ([@bib65]), and WW motifs recognize proline-rich ligands, also in conjunction with S/T phosphorylation ([@bib15]; [@bib21]; [@bib30]). Mutation of T292 in the proline-rich region of MEK1 to a nonphosphorylatable A (T292A) decreased, and a phosphomimetic (T292D) mutation increased, binding to MAGI1 and WW, but not GUK ([Figures 5](#fig5){ref-type="fig"}C--5E). Thus, if the GUK domain is phosphosensitive, binding must depend on a different phosphorylation site. Mutation of the WW domains of MAGI1, in particular of WW2, strongly reduced MEK1 binding by a WW MAGI1 fragment or by full-length MAGI1 ([Figures 5](#fig5){ref-type="fig"}F and 5G). Remarkably, a MAGI1 GUK-WW fragment, which binds to MEK1 but not to PTEN, strongly reduced the binding of endogenous MEK1 and MAGI1 to PTEN, reduced PTEN membrane recruitment, and triggered AKT hyperactivation ([Figures 5](#fig5){ref-type="fig"}H and 5I), mimicking the MEK1 KO. A MAGI1 GUK-WW2 domain mutant was less efficient in preventing MEK1/MAGI1 binding to PTEN and causing AKT activation ([Figure 5](#fig5){ref-type="fig"}H). The residual MEK1 binding/dominant negative activity of the MAGI1 GUK-WW2 domain mutant is likely due to the interaction of the MAGI1 GUK domain with other MEK1 binding sites ([Figures 5](#fig5){ref-type="fig"}A, 5B, and 5D). Together, the data support the hypothesis that perturbations of the ternary complex PTEN/MAGI/MEK1 result in AKT activation.

MEK1 T292 Phosphorylation Controls Complex Formation {#sec2.5}
----------------------------------------------------

To further investigate the role of T292, we monitored complex formation in KO MEFs reconstituted with nonphosphorylatable T292A or phosphomimetic T292D MEK1 mutants. The mutants expressed at comparable levels, slightly lower than WT MEK1. MAGI1~100~ formed a complex with PTEN in WT and T292D cells, but not in KO or T292A cells; in addition, complex formation between MAGI1, PTEN, and the phosphomimetic MEK1 T292D mutant was not regulated by growth factor treatment ([Figure 6](#fig6){ref-type="fig"}A).

Like KO MEFs, MEK1 T292A cells showed defective PTEN membrane recruitment, and PIP~3~ accumulation and AKT phosphorylation were increased above the levels observed in KO cells. The exact reasons for these differences between KO and reconstituted cells are unknown. In contrast, MEK1 T292D mutant cells displayed constitutive PTEN membrane recruitment, as well as low levels of PIP~3~ and AKT phosphorylation ([Figures 6](#fig6){ref-type="fig"}B--6D). Consistent with this biochemical behavior, MEK1 T292A cells were resistant to TNFα-induced apoptosis ([Figure S5](#app2){ref-type="sec"}A). Thus, T292 phosphorylation is a prerequisite for proper complex formation and for the regulation of the PIP~3~ pathway.

T292 is phosphorylated by ERK, which might thus regulate the timing of PTEN membrane recruitment and AKT signaling. Indeed, MEK inhibitors blocked both ERK and T292 phosphorylation, concomitantly increasing AKT phosphorylation ([Figures 6](#fig6){ref-type="fig"}E and [S5](#app2){ref-type="sec"}B) and PIP~3~ accumulation ([Figure 6](#fig6){ref-type="fig"}F) and, most importantly, reducing the binding of MEK1 and MAGI1~100~ to PTEN and of MAGI1~100~ to MEK1 ([Figures 6](#fig6){ref-type="fig"}G and 6H). In MEK1 T292D MEFs, MEK inhibition did not perturb the association of PTEN with MEK1 or MAGI1~100~ or AKT phosphorylation ([Figures 6](#fig6){ref-type="fig"}I and 6J); thus, phosphorylation of T292 is required, and MEK1 kinase activity is dispensable, for the interaction of MEK1 with MAGI~100~ and PTEN.

Two other MAGI family proteins, MAGI2 and MAGI3, were also able to form complexes with MEK1. Consistent with the data obtained for MAGI1, chemical inhibition of T292 phosphorylation decreased the recruitment of MAGI2 and 3 to the membrane ([Figures S5](#app2){ref-type="sec"}C and S5D).

Discussion {#sec3}
==========

A Kinase-Independent Role for MEK1 in the Regulation of PTEN Function {#sec3.1}
---------------------------------------------------------------------

We report the existence of a ternary complex between MEK1, MAGI1, and PTEN, mediating the translocation of PTEN to the membrane and therefore regulating the concentration of PIP~3~ and AKT activation. Both MEK1 and MAGI1 are necessary for complex formation, and PTEN will not bind to one component if the other is missing. The complex is held together by MAGI1, which contacts PTEN via its PDZ domain ([@bib24]) and MEK1. MAGI1 binds to MEK1 via its GUK and WW2 domains, but only binding to the WW domains is sensitive to the ERK-mediated phosphorylation of T292 in MEK1. The MAGI1 WW domains are very similar to the group Ib WW2 and WW3 domains of the ubiquitin ligase Nedd4L, whose binding to SMAD2 and SMAD3 depends on the phosphorylation of a T in the linker region ([@bib15]); the NEDD4 WW2 domain has been found to bind to proteins containing PR sequences in an unbiased proteomic screen ([@bib21]). T292 of MEK1 is embedded in such a PR containing sequence (PPRPRTPGRP in MEK1, SPRPRPPGRP in MEK2); in addition, the MEK1 sequence does not contain any other predicted WW binding sites. Since the proline-rich loop of MEK1 is disordered in all available crystal structures, its interaction with the MAGI1 WW domains cannot be modeled, and at this point it is not possible to distinguish whether phosphorylation creates a reversible MAGI1 binding site on MEK1 or induces exposure of another MAGI1 binding site through an allosteric mechanism.

Besides being essential for the assembly of the MEK1/MAGI/PTEN complex, pT292 is also required for the downregulation of MEK2-dependent ERK signaling, mediated by MEK1 in the context of a MEK1/MEK2 heterodimer ([@bib8]). Thus, phosphorylation of MEK1 T292 relays a negative feedback within the ERK pathway and initiates the deactivation of the PIP~3~/AKT pathway through the membrane localization of MAGI/PTEN, acting as a temporal switch for both cascades.

MEK1 has been reported to bind to another WW domain containing protein, namely the proapoptotic tumor suppressor WOX1, associated with the death of activated T cell leukemia. In this case, however, the WOX1/MEK1 complex dissociates upon ERK activation ([@bib27]). Thus, ERK differentially regulates binding of MEK1 to WW domain containing proteins and may negatively affect survival by promoting the translocation of WOX1 to the mitochondria ([@bib27]) and the membrane recruitment of PTEN in the context of the MEK1/MAGI1/PTEN complex.

Our data show that MEK1 binding to the GUK and WW domains of MAGI1 promotes both complex formation between MAGI1 and PTEN and their membrane translocation. We do not know in detail how this is accomplished. One hypothesis is that binding to MEK1 will cause a conformational change in MAGI1, exposing the PDZ domains necessary for PTEN binding (PDZ2 \[[@bib24]\]) and for the binding to membrane proteins such as cadherins (PDZ4 and PDZ5 \[[@bib24]; [@bib33]; [@bib59]\]). Intramolecular interactions between the SH3 and the GUK domain of other MAGUK proteins have been described, postulated to keep the proteins in an inactive, "closed" conformation ([@bib34]). In MAGI, the WW domain replaces the SH3. It is conceivable that the WW domain may also be involved in intramolecular interactions that can be interrupted by MEK1 binding. Whatever the mechanism involved, MEK1 kinase activity is not required for complex formation and MEK1 binds to MAGI1 as a monomer or as a MEK1 dimer, but not as a heterodimer.

It is noteworthy that MEK1, but not PTEN, binds selectively to MAGI~100~, the only isoform translocated to the membrane in response to growth factors. Binding of PTEN to other MAGI1 isoforms may localize the phosphatase to other subcellular compartments, such as the nucleus ([@bib12]; [@bib25]), but it does not rescue membrane recruitment in the absence of MEK1. In addition, MAGI1~100~ is selectively expressed in organs and cells that are affected by MEK1 ablation (compare thymus and spleen in [Figure 4](#fig4){ref-type="fig"}F), where it correlates with the lack of PTEN membrane recruitment.

The possibility also exists that it is MEK1, rather than MAGI1, that mediates the membrane recruitment of the ternary complex. In this context, MEK reportedly binds to paxillin, and growth factor treatment induces the recruitment of Raf and ERK to this complex. Activated ERK phosphorylates paxillin on S83, promoting its association with activated FAK and PI3K and increasing cell spreading ([@bib22]). The study did not differentiate between MEK1 and MEK2; however, our data would predict that in the absence of MEK1 at least a certain number of focal adhesions would fail to recruit MAGI/PTEN, resulting in the increased FAK phosphorylation, growth factor-induced migration, and cell spreading ([@bib8]) observed in the MEK1 KO fibroblasts.

Finally, some PTEN membrane binding, unaffected by EGF stimulation, can be observed in MEK1 KO fibroblasts (on average, approximately 20% of the WT). It is conceivable that this binding is mediated by the N-terminal PIP~2~-binding motif of PTEN, which has been shown to be necessary for membrane association ([@bib38]). Alternative binding mechanisms likely underlie the rather modest EGF-mediated membrane recruitment of PTEN and MEK1, compared with the robust increase of MAGI1; consistent with this, a strong increase in the amount of both MEK1 and MAGI1~100~ is observed in membrane PTEN IPs from stimulated cells, indicating that EGF causes the preferential recruitment of the ternary complex to the membrane.

Together, these data define a unique kinase-independent function of MEK1 outside the canonical pathway and provide insight into PTEN regulation.

Biological Implications of a Disabled Feedback {#sec3.2}
----------------------------------------------

MEK1 KO mice succumb early to an autoimmune disease accompanied by extramedullary hematopoiesis. The latter phenotype has been observed in PTEN cell-type-restricted KO or AKT transgenic mice ([@bib18]; [@bib23]; [@bib61]), and we could show that KO bone marrow and spleen from unaffected animals contain significantly higher numbers of colony forming units, indicating a cell-autonomous phenotype. At this point, however, the contribution of the MEK1 KO environment, with its lymphoid dysregulation and autoimmune disease, is unclear. Cell-type-restricted MEK1 ablation and transplantation experiments are planned to clarify this matter.

The autoimmune disease clearly correlates with a reduction in T cell activation-induced cell death and with AKT activation in T cells and kidney. A similar phenotype can be achieved by genetic manipulations increasing PIP~3~/AKT signaling ([@bib5]; [@bib11]; [@bib29]; [@bib35]; [@bib49]), but also by adoptive transfer of mouse T lymphocytes treated ex vivo with MEK inhibitor ([@bib10]) or T cell restricted expression of a dominant negative *mek* transgene ([@bib43]). The latter treatments would mimic the MEK1 KO by reducing phosphorylation of the critical T292 residue in MEK1 and therefore PTEN membrane recruitment. Importantly, both reduced ERK activation ([@bib17]) and increased AKT signaling ([@bib52]) have been observed in T cells from lupus patients. Together with our data, these results suggest that the activation of ERK and its crosstalk with the PI3K pathway are crucial players in the development of experimental and possibly clinical lupus-like autoimmune diseases.

The MEK1 KO does not phenocopy T cell-restricted PTEN deletion in two aspects: the breach of central tolerance ([@bib49]) and the development of T cell lymphomas ([@bib29]). In both cases, the cells responsible for the phenotype originate in the thymus, which is not affected in the MEK1 KO mice. This lack of phenotype correlates with the lack of expression of MAGI~100~, and underscores the specific effect of MEK1 on this particular mechanism of PTEN regulation. In this context, it is important to consider that the impaired membrane localization of MAGI-1 in KO cells and organs might cause deregulation/mislocalization of one or more of its many interaction partners, thereby playing a role in the phenotype of the MEK1 KO mice.

Is the regulation of PTEN by MEK1/MAGI relevant in the context of cancer? MAGI has been found mutated in human cancer genomes ([@bib2]; [@bib36]), and it can suppress the growth of tumor xenografts ([@bib63]). Based on this, it is in principle possible that MEK1 may act as a tumor suppressor under certain conditions, as observed in a model of Myc-induced B cell lymphoma ([@bib6]). More broadly, inhibition of the Raf/MEK/ERK pathway often causes activation of the AKT pathway in cancer ([@bib19]; [@bib32]; [@bib57]), due to the release of yet incompletely identified negative feedback loops. The use of Raf or MEK inhibitors might, by preventing the phosphorylation of T292 in MEK1, decrease PTEN membrane recruitment, increasing PIP~3~ concentrations and favoring the emergence of resistance mechanisms relying on the PI3K/AKT pathway. This would provide a mechanistic framework for the combined inhibition of these pathways, which is being increasingly advocated as the treatment of choice ([@bib20]; [@bib46]; [@bib56]).

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

*mek1*^*f/f*^*; Sox2Cre* mice ([@bib8]) were maintained on a mixed Sv129/Bl6 background. Animal experiments were performed in accordance with a protocol authorized by the Austrian Ministry of Science and Communications.

Cell Culture and Transfections {#sec4.2}
------------------------------

MEFs and stable KO clones re-expressing WT and mutant MEK1 ([@bib8]) were grown in Dulbecco's modified Eagle's medium plus 10% (v/v) fetal calf serum (FCS) (PAA) and starved in 0.5% (v/v) FCS overnight prior to treatment with EGF (2 ng/ml, Biomedical Technologies). Inhibitors (10 nM PD0325901, Sigma-Aldrich; 10 μM U0126 and 50 μM LY294002, Cell Signaling) were added 1 hr before stimulation. MEFs were transfected with 30 nM MAGI siRNA duplexes ([@bib41]) or nontargeting pool (D-001810-10-05, Dharmacon) with Lipofectamine RNAiMAX (Invitrogen). COS-7 cells were transfected with TurboFect (Fermentas).

Splenic CD4+ T and B cells were purified with MACS negative selection kits (MiltenyiBiotec; purity approximately 95% by fluorescence-activated cell sorting \[FACS\]) and cultured in RPMI 1640 (PAA) plus 10% FCS, 1 mM sodium pyruvate (Sigma-Aldrich), 1% nonessential amino acids (Sigma-Aldrich), 50 μM β-ME, and 10 mM N-acetylcysteine. In T cells, AICD was induced with anti-CD3/CD28 (1 μg/ml and 0.5 μg/ml, both BD PharMingen) for 72 hr, followed by 16 hr stimulation with αCD3 (10 μg/ml). B cells were treated with soluble anti-IgM Fab~2~ fragment (0.1 μg/ml, Jackson ImmunoResearch) and analyzed 24 hr later. FasL (100 ng/ml, Adipogen) induced apoptosis was monitored 6 hr after the treatment. Cell death was measured by annexinV/propidium iodide staining (eBiosciences).

Immunoprecipitation, Pull-Down, Cell Fractionation, Immunoblotting, ELISA, and ELISpot {#sec4.3}
--------------------------------------------------------------------------------------

Cells were lysed in a buffer containing 20 mM TrisHCl (pH 7.4), 137 mM NaCl, 1 mM CaCl~2~, 1 mM MgCl~2,~ 1% NP-40, 1 mM Na~3~VO~4~, 50 mM NaF, 2 mM PMSF, and protein inhibitor cocktail (Roche). IPs were prepared by addition of the appropriate antibodies prior to incubation with protein A-sepharose (GE Healthcare) or protein G-agarose (Thermo Scientific). Phosphatase activity in PTEN IPs was monitored as described ([@bib42]). Pull-down experiments were carried out in IP buffer plus 0.1% BSA with purified recombinant PTEN (Calbiochem) and MEK1 (gift of I. Moarefi, Crelux). The Thermo Scientific or ProteoJet membrane protein extraction kit (Fermentas) or hypotonic lysis/differential centrifugation were used to produce cytoplasmic and membrane (plasma, mitochondria, and ER/Golgi) fractions. Immunoblotting was performed with the antibodies detailed in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}. Echelon kits were used to determine PIP~3~ levels (mass ELISA) and PI3K activity (ELISA). Serum antibodies, BAFF, and IL-10 were detected by ELISA (Life Diagnostics and R&D Systems). ELISpot assays were performed with IgA and IgG ELISpot kits (Mabtech).

Immunofluorescence {#sec4.4}
------------------

Anti-dsDNA antibodies were detected by *Crithidia luciliae* (Orgentec) kinetoplast staining with FITC-conjugated goat anti-mouse Ig antibody (Invitrogen). Confocal images were acquired with LSM Meta (Zeiss). For details, see the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Blood Analysis and FACS {#sec4.5}
-----------------------

Peripheral blood cell counts were acquired with V-Sight (Menarini Diagnostics). Cells were stained with antibodies against CD19, CD3e, CD4, CD8a, Mac1, Gr-1, and CD69 (all BD PharMingen) and analyzed by FACSCalibur and FACSAria (BectonDickinson) and FlowJo software.

Histology and Immunohistochemistry {#sec4.6}
----------------------------------

Hematoxylin and eosin staining and immunohistochemistry were carried out as described ([@bib8]) with pAKT (S473) and pERK (T202/Y204; both Cell Signaling). Reticular fibers were visualized by Gomori staining. Frozen kidney sections were examined as described in ([@bib11]).

Statistical Analysis {#sec4.7}
--------------------

Values are expressed as mean (±SD) of at least three independent experiments. p values were calculated with the two-tailed Student's t test. A p value ≤0.05 is considered statistically significant.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S5 and Supplemental Experimental Procedures

We thank I. Moarefi, E. Ogris, and Z. Xu for providing material, N. Kozakowski for helpful discussions, and N. Seiter and the animal facility for technical assistance. This work was supported by FWF grants T 196-B12 to V.J. and W1220-B09 to M.B.

Supplemental Information includes five figures and Supplemental Experimental Procedures and can be found with this article online at [http://dx.doi.org/10.1016/j.molcel.2013.01.037](10.1016/j.molcel.2013.01.037).

![MEK1 Ablation Promotes PIP~3~ Signaling by Preventing PTEN Membrane Translocation\
(A--C) WT and KO MEFs (A and C), and KO MEFs reconstituted with full-length MEK1 (+FL MEK1) or empty vector (+EV) (B) were stimulated with EGF and lysed at the indicated time points. Proteins and phosphorylated proteins were detected by immunoblotting as indicated.\
(D) ELISA measurement of cellular PIP~3~ in MEFs upon EGF stimulation.\
(E) PI3K activity in p85 IPs from untreated or EGF-stimulated MEFs was assessed by ELISA. The amount of PIP~3~ was normalized to the amount of immunoprecipitated p85.\
(F) Extracts of starved or EGF-stimulated MEFs separated into cytosolic and membrane fractions. The presence of PTEN, MEK1, GAPDH (cytosolic marker), and IGF1R (plasma membrane marker) was assessed by immunoblotting.\
(G) PTEN activity in membrane and cytosol fractions of EGF-stimulated MEFs. In the middle and bottom panels, arbitrary units were calculated by division of picomoles of released phosphate by the amount of immunoprecipitated PTEN determined by the densitometry of western blots.\
The values in (D), (E), and (G) represent the mean of three experiments ±SD. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S1](#app2){ref-type="sec"}.](gr1){#fig1}

![Myeloproliferation and Lymphocyte Activation in MEK1 KO Mice\
(A) Survival of female (n = 28) and male (n = 17) KO mice monitored over a 15 month period.\
(B) Peripheral blood cell counts of young (1--3 months) and old (8--12 months) female KO mice and sex-matched WT littermates. Values represent mean ±SD (n = 5).\
(C and D) Spleno- and hepatomegaly in MEK1 KO mice. The plots show the weight of spleens (C; n = 6) and livers (D; n = 5) isolated from affected mice.\
(E) Effacement of tissue architecture, extramedullary hematopoiesis (hematoxylin and eosin staining; arrowhead, giant megakaryocyte) and fibrosis in KO livers and spleens. Scale bars represent 200 μm.\
(F and G) Increased Mac1^+^/Gr1^+^ cells and activated lymphocytes in spleens of affected KO mice (age 5--12 months, n = 5), detected by FACS analysis of lineage-specific and activation-induced markers (G; CD69).\
Values represent mean ±SD (n = 5). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S2](#app2){ref-type="sec"}.](gr2){#fig2}

![MEK1 Ablation Leads to Systemic Autoimmune Disease\
(A) Enlarged glomeruli (arrows), tubules filled with proteinaceous material (asterisk), and increased pAKT in KO kidneys. Scale bars represent 100 μm.\
(B) Immune complex deposition in the glomerulus of a 10-month-old KO female visualized by mouse IgG antibodies (green). The scale bar represents 30 μm.\
(C) dsDNA autoantibodies detected in the serum of KO mice (5--10 months, n = 7) by *Crithidia luciliae* kinetoplast staining.\
(D) IgG1, IgG2b, and IgA levels in the sera of 8- to 10-month-old mice (n = 3) assessed by ELISA.\
(E) Frequency of B cells secreting IgA and IgG in 8- to 10-month-old mice determined by ELISpot (n = 4). Error bars represent the SD.\
(F) BAFF and IL-10 serum levels determined as in (D).\
(G) AKT phosphorylation and expression of AKT, MEK1, and GAPDH (loading control) were determined in lysates of 8-week-old WT and KO spleens.\
(H) PTEN, MEK1, GAPDH (cytosolic marker), and caveolin (membrane marker) detected by immunoblotting in subcellular fractions of freshly isolated WT and KO splenocytes.\
(I) Splenic CD4+ T cells stimulated with anti-CD3 and anti-CD28 (3 μg/ml each). The indicated proteins were visualized by immunoblotting.\
(J--L) Survival of CD4+ T cells and B cells in response to AICD and FasL-induced cell death.\
Values represent the mean of three experiments ±SD. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S3](#app2){ref-type="sec"}.](gr3){#fig3}

![A MEK1/MAGI1/PTEN Ternary Complex Regulates MAGI1 and PTEN Membrane Recruitment\
(A and B) MEK1 (A) or PTEN (B) IPs prepared from EGF-stimulated WT and KO MEFs. MEK1, MEK2, and PTEN were detected by immunoblotting. WCL, whole-cell lysates; c, unspecific binding to beads or isotype control antibody (IgG).\
(C) Translocation of MAGI1~100~ (^∗^) and PTEN to the membrane. MAGI1, PTEN, IGF1R (membrane marker), and GAPDH (cytosolic marker) detected by immunoblotting of cytosol and membrane fractions of EGF-stimulated MEFs.\
(D) PTEN, MAGI1, MEK1, and pMEK1 (pS298, pT292, and Raf-dependent sites, pRDS) detected by immunoblotting in WCL and PTEN IPs from EGF-stimulated MEFs.\
(E) PTEN was immunoprecipitated from EGF-stimulated (30 min) WT and KO MEFs. Recombinant MEK1 (rMEK1; 1 μg) was added to the KO lysate as indicated. rMEK1 lacks 34 N-terminal amino acids and runs faster than endogenous MEK1.\
(F) WCL and PTEN IPs from WT and KO thymocytes and splenocytes immunoblotted with PTEN, MAGI1, and MEK1 antibodies.\
(G) WT MEFs transfected with small interfering RNA (siRNA) against MAGI1 or control siRNA (scrambled). PTEN, MAGI1, and MEK1 were detected by immunoblotting of WCL and PTEN IPs from EGF-stimulated cells (30 min) MEFs.\
See also [Figure S4](#app2){ref-type="sec"}.](gr4){#fig4}

![Structure-Function Analysis of MEK1/MAGI1 Complexes\
COS7 cells continuously growing in the presence of serum were transiently transfected with the indicated constructs.\
(A) myc-tagged MAGI1 domains (schematically depicted in the upper panel) in endogenous MEK1 IPs and WCL were detected by immunoblot.\
(B) myc-tagged MAGI1 and endogenous MEK1 were detected in myc-tag IPs and WCL of cells transfected with myc-tagged MAGI1 deletion mutants.\
(C--E) myc-tagged MAGI1 proteins and His-tagged MEK1 were detected in myc-tag IP and WCL of cells transfected with His-tagged WT or mutant MEK1 and myc-tagged full-length MAGI1 (C), GUK (D), or WW (E) domains. Lysates were subjected to immunoblotting with His and myc antibodies.\
(F and G) myc-tagged MAGI1 proteins and endogenous MEK1 were detected by immunoblotting in myc-tag IPs and in lysates of cells transfected with WT or mutant WW domains of MAGI1 (1, 2, and D, double mutant; F) or full-length MAGI1 bearing the same mutations (G). EV, empty vector.\
(H and I) COS7 cells transfected with a plasmid encoding the WT or mutated GUK-WW domains of MAGI1 or EV were subjected to PTEN IP (H). The indicated antigens were detected by immunoblotting. PTEN membrane localization was assessed by immunofluorescence (I; n = 3). Values represent mean ± SD. ^∗∗^p \< 0.01.\
The numbers in (B), (F), and (G) indicate the ratio between MEK1:myc-MAGI1 proteins, measured by densitometry. The MEK1:WT myc-MAGI1 ratio is set as 1.](gr5){#fig5}

![T292 Phosphorylation, but Not MEK1 Kinase Activity, Promotes MEK1/MAGI1/PTEN Binding and Decreases PIP~3~ Pathway Activation\
(A) WT, KO, and MEK1 mutant fibroblasts were stimulated with EGF. PTEN, MAGI1, and MEK1 in endogenous PTEN IPs and WCL were detected by immunoblotting.\
(B--D) MEK1 WT, KO, and mutant fibroblasts were stimulated with EGF. PTEN membrane recruitment was determined by immunofluorescence. The plot in (B) depicts the percentage of cells showing membrane PTEN. The plot in (C) shows PIP~3~ levels, determined by ELISA. pAKT, pERK, AKT, MEK, and tubulin (loading control) were detected by immunoblotting (D).\
(E and F) WT MEFs were pretreated with MEK inhibitors or DMSO and stimulated with EGF. Phosphorylation and expression of AKT, ERK, MEK1, and tubulin (loading control) were determined by immunoblotting (E). Intracellular PIP~3~ levels in WT MEFs pretreated with U0126 or DMSO and stimulated with EGF were measured by ELISA (F).\
(G and H) WT fibroblasts pretreated with DMSO or MEK inhibitors (U0126, PD0325901) and stimulated with EGF were subjected to PTEN (G) or MEK1 IP (H). PTEN, MAGI1, and MEK1 were detected by immunoblotting. c, nonspecific binding to the beads.\
(I and J) T292D MEK1 mutant MEFs were treated with U0126 or DMSO and stimulated with EGF. PTEN, MEK1, and MAGI1 in PTEN IPs (I) and pAKT, AKT, and GAPDH (loading control) in WCL (J) were visualized by immunoblotting. In (J), c represents nonspecific binding to the beads.\
The values in (B), (C), and (F) show the mean of three experiments ±SD. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. See also [Figure S5](#app2){ref-type="sec"}.](gr6){#fig6}
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